Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Laureate To Manufacture Tolera's Monoclonal Antibody Product
Laureate Pharma, Inc. announced that it has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, Inc.. According to the agreement, Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the manufacturing agreement were not disclosed.
"We are pleased to work closely with Tolera to accelerate their antibody therapeutics program to clinic," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate. "We are committed to providing Tolera with superior services to help them achieve their manufacturing objectives."
"We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans," said John J. Puisis, President and Chief Executive Officer of Tolera. "We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous